CEL-SCI Co. (NYSE:CVM) SVP Acquires $11,120.00 in Stock

CEL-SCI Co. (NYSE:CVM) SVP Patricia B. Prichep acquired 8,000 shares of the firm’s stock in a transaction on Wednesday, May 8th. The shares were acquired at an average price of $1.39 per share, with a total value of $11,120.00. Following the completion of the transaction, the senior vice president now directly owns 232,326 shares in the company, valued at approximately $322,933.14. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

CEL-SCI Stock Down 2.6 %

NYSE CVM traded down $0.04 during trading on Friday, reaching $1.47. 223,445 shares of the company’s stock were exchanged, compared to its average volume of 333,082. CEL-SCI Co. has a fifty-two week low of $1.04 and a fifty-two week high of $3.23. The firm has a market capitalization of $79.35 million, a PE ratio of -2.18 and a beta of 1.23. The company has a current ratio of 1.26, a quick ratio of 0.78 and a debt-to-equity ratio of 0.75. The company’s fifty day simple moving average is $1.79 and its 200-day simple moving average is $2.21.

CEL-SCI (NYSE:CVM) last announced its quarterly earnings data on Wednesday, February 14th. The company reported ($0.14) EPS for the quarter. Sell-side analysts predict that CEL-SCI Co. will post -0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered CEL-SCI from a “hold” rating to a “sell” rating in a research report on Friday, March 15th.

Institutional Investors Weigh In On CEL-SCI

Several institutional investors have recently made changes to their positions in the company. CVI Holdings LLC acquired a new stake in shares of CEL-SCI during the 1st quarter valued at about $1,678,000. D.A. Davidson & CO. lifted its holdings in shares of CEL-SCI by 564.2% during the 4th quarter. D.A. Davidson & CO. now owns 290,928 shares of the company’s stock valued at $791,000 after buying an additional 247,128 shares during the last quarter. Thoroughbred Financial Services LLC lifted its holdings in shares of CEL-SCI by 24.6% during the 4th quarter. Thoroughbred Financial Services LLC now owns 126,761 shares of the company’s stock valued at $344,000 after buying an additional 25,000 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new stake in shares of CEL-SCI during the 4th quarter valued at about $329,000. Finally, Cutter & CO Brokerage Inc. lifted its holdings in shares of CEL-SCI by 20.5% during the 3rd quarter. Cutter & CO Brokerage Inc. now owns 102,845 shares of the company’s stock valued at $129,000 after buying an additional 17,500 shares during the last quarter. 12.08% of the stock is currently owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.